

PRECEPTORSHIP PROGRAMME

Gastric Cancer

Multidisciplinary management,
standards of care, therapeutic
targets and future perspectives

VALENCIA
SPAIN

25-26 OCTOBER 2019

Co-Chairs

Andrés Cervantes, ES
Florian Lordick, DE

ESMO PRECEPTORSHIP PROGRAMME GASTRIC CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Valencia, Spain
25-26 October 2019

CO-CHAIRS: Andrés Cervantes, Spain
Florian Lordick, Germany

SPEAKERS: William Allum, United Kingdom
Fatima Carneiro, Portugal
Karin Haustermans, Belgium
Javier Sempere, Spain
Elizabeth Smyth, United Kingdom

LEARNING OBJECTIVES

- To learn about the fundamentals of epidemiology, aetiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 25 October 2019

09:00-09:10 10'	Opening and welcome	
10'	Welcome from ESMO and introduction	Andrés Cervantes, ES Florian Lordick, DE
09:10-11:25 135'	SESSION 1 Epidemiology, pathology and endoscopy of gastric cancer	Fatima Carneiro, PT
30'	Epidemiology (including GE junction tumours) and clinical presentation	Andrés Cervantes, ES
60'	Pathology and carcinogenesis and its potential clinical impact	Fatima Carneiro, PT
30'	Endoscopy in gastric cancer: New imaging techniques, new treatment modalities (EMR, ESD)	Javier Sempere, ES
15'	Discussion	Faculty
11:25-11:55	Coffee break	
11:55-13:25 90'	SESSION 2 Surgical, adjuvant and neoadjuvant treatment of gastric cancer	Karin Haustermans, BE
30'	Surgery for gastric and GE junction cancer, primary, palliative - where and when?	William Allum, UK
25'	Neo- and adjuvant treatment for gastric cancer and GE junction cancer: The role of radiotherapy	Karin Haustermans, BE
25'	Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy	Elizabeth Smyth, UK
10'	Discussion	Faculty
13:25-14:30	Lunch	
14:30-15:10 40'	SESSION 3 Clinical discussions	Florian Lordick, DE
30'	Clinical case on sequential treatment of advanced gastric cancer	Florian Lordick, DE
10'	Discussion	Faculty
15:10-15:30	Coffee break	
15:30-17:30 120'	SESSION 4 Advanced disease	Florian Lordick, DE
30'	Chemotherapy	Andrés Cervantes, ES
40'	Biologically targeted treatment	Florian Lordick, DE
40'	Immunotherapy	Elizabeth Smyth, UK
10'	Discussion	Faculty
20:30	Dinner	

Saturday, 26 October 2019

09:00-10:30 90'	SESSION 5 Case discussion based on ESMO Clinical Practice Guidelines I	Florian Lordick, DE Andrés Cervantes, ES
6x15'	6 x Participants clinical case discussion	Faculty
10:30-11:00 Coffee break		
11:00-12:30 90'	SESSION 6 Case discussion based on ESMO Clinical Practice Guidelines II	Florian Lordick, DE Andrés Cervantes, ES
6x15'	6 x Participants clinical case discussion	Faculty
12:30-12:50 20'	Future outlook, conclusion and farewell	Andrés Cervantes, ES
12:50-14:00 Lunch		

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion